Replies to post #616136 on NorthWest Biotherapeutics Inc (NWBO)

[CrashOverride]

NICE will appraise DCVax at the same time MHRA issues marketing approval.

They will fully reimburse DCVax given high QALY threshold of 100K for orphan and rare disease patients which Glioblastoma qualifies as both.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169141878

Rumors spread by Poor Man are yet again proven false.